DUBLIN–(BUSINESS WIRE)–The “China Contract Research Organization (CRO) Industry Report, 2020-2026” report has been added to ResearchAndMarkets.com’s offering.
In 2020, the world CRO market is expected to be worth $69.9 billion with a year-on-year spike of 9%.
The contract research organization (CRO) industry has been galloping amid the global pharmaceutical market steadily in headway, the vibrant financing in the medical and health sector, and the proliferating expenses for pharmaceutical R&D.
Competition pricks up among at least 1,100 CRO players worldwide led by LabCorp, IQVIA, Syneos, Parexel, PRA, PPD, and Charles River. In 2019, IQVIA, LabCorp and Syneos were the three leaders sweeping a combined market share of 21.5%.
China’s great competitive edge over the developed countries in pharmaceutical R&D cost has allured many world-renowned pharmaceutical corporations and boosted the country’s CRO industry. With speedy development over a decade, China has been an important CRO market whose market size in 2020 will soar 10.1% on an annualized basis and reach RMB81.6 billion.
In addition to multinational giants represented by IQVIA, LabCorp, Parexel, etc., China also sees local CRO leaders including Wuxi AppTec, Pharmaron, Meidicilon, Shanghai ChemPartner, Tigermed, and Joinn Laboratories, where Wuxi AppTec with the strongest R&D strength as one of the most comprehensive service platforms integrating discovery, research and development of small-molecule chemical drugs, not only runs the China’s largest small-molecule pharmaceutical R&D service business but leads the way in global market. It enjoyed a virtually 12.3% (up 1.8 percentage points over the prior year) of the world’s CRO market in 2019.
China’s CRO industry will be heading towards:
China Contract Research Organization (CRO) Industry Report, 2020-2026 highlights:
Key Topics Covered:
1. Overview of Pharmaceutical Outsourcing
1.1 Definition
1.2 Classification
1.3 CRO
2. Evolution of Global CRO Industry
2.1 Development History
2.2 Development Background
2.2.1 Pharmaceutical Industry Size
2.2.2 Pharmaceutical Companies Development
2.2.3 Financing
2.2.4 Pharmaceutical R&D
2.3 Market Size
2.4 Competitive Landscape
3. CRO Industry in China
3.1 Development Environment
3.1.1 Regulation
3.1.2 Policy Environment
3.1.3 Industry Environment
3.2 Status Quo
3.3 Market Size
3.4 Competitive Landscape
3.5 Development Trend
3.5.1 The Amounting Pressure from R&D Costs Make Pharmaceutical Enterprises Rely More on CRO Companies for the Research and Development of New Drugs
3.5.2 Favorable policies and capital promote the development of local Chinese companies
3.5.3 Good Prospects Attract the Enterprises’ Access into CRO Industry
3.5.4 The Industry Heads toward Vertical Integration
3.5.5 M&A May Become the Main Way for CRO Companies to Expand
3.5.6 The Comprehensive Implementation of Consistency Assessment Brings Development Opportunities to the CRO Industry
3.5.7 Industry threshold and concentration degree rises gradually
3.5.8 Specialization and characterization are becoming ever more obvious
4. Major Chinese Companies
4.1 Wuxi AppTec
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 Major Clients
4.1.6 R&D Investment
4.1.7 CRO Business
4.1.8 Development Strategy
4.2 Hangzhou Tigermed
4.3 Guangzhou Boji Pharmaceutical
4.4 Shanghai Meidicilon Inc.
4.5 Porton Fine Chemicals
4.6 Joinn Laboratories
4.7 Pharmaron
4.8 Obio Technology (Shanghai)
4.9 Nanjing Huawe Medicine Technology Group Co., Ltd.
4.10 Shanghai ChemPartner
4.11 HitGen Inc.
4.12 BioDuro
4.13 VIVA Biotech
5 Major Foreign Companies
5.1 LabCorp
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 CRO Business
5.1.5 Development in China
5.2 IQVIA
5.3 Parexel
5.4 Charles River
5.5 PPD
5.6 Syneos Health
5.7 PRA
5.8 ICON
For more information about this report visit https://www.researchandmarkets.com/r/2jml4z
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei announced today that it will construct…
PASCARI brings Boot, SATA, Data Center, and high-performance X-Series to channel expanding Phison’s market share…
LONG BEACH, Calif.--(BUSINESS WIRE)--#Laserfiche--Laserfiche — the leading SaaS provider of intelligent content management and business…
One of the singular largest loans in the bank’s decades-long history supports Thailand's ambitious Bio-Circular-Green…
– Building a partnership towards commercialization of Level 4 autonomous driving in 2027 – MOUNTAIN…
Global healthcare management organization benefit from the flexibility, cost-savings, and quality support gained by choosing…